Literature DB >> 19762492

Donor age and renal P-glycoprotein expression associate with chronic histological damage in renal allografts.

Maarten Naesens1, Evelyne Lerut, Hylke de Jonge, Boudewijn Van Damme, Yves Vanrenterghem, Dirk R J Kuypers.   

Abstract

The contributions of donor kidney quality (partially determined by donor age), allograft rejection, and calcineurin inhibitor nephrotoxicity on the progression of histologic damage of renal allografts are not completely defined. Moreover, the determinants of individual susceptibility to calcineurin inhibitor nephrotoxicity are not known but may include variability in drug transport and metabolism. In a prospective cohort of 252 adult renal allograft recipients treated with a combination of tacrolimus, mycophenolate mofetil, and corticosteroids, we studied 744 renal allograft biopsies obtained regularly from time of transplantation for 3 yr. We assessed determinants of histologic evolution, including tacrolimus exposure, renal P-glycoprotein (ABCB1) expression, and polymorphisms in the CYP3A4, CYP3A5, and ABCB1 genes. Within the first 3 yr after transplantation, we noted a progressive increase in interstitial fibrosis, tubular atrophy, glomerulosclerosis, and vascular intimal thickening. Older donor age, absence of P-glycoprotein expression at the apical membrane of tubular epithelial cells, and combined donor-recipient homozygosity for the C3435T variant in ABCB1 significantly associated with increased susceptibility to chronic allograft damage independent of graft quality at implantation. Changes in graft function over time reflected these associations with donor age and ABCB1 polymorphisms, but it was acute T cell-mediated and antibody-mediated rejection that determined early graft survival. In conclusion, the effects of older donor age reach beyond the quality of the allograft at implantation and continue to be important for histologic evolution in the posttransplantation period. In addition, ABCB1 genotype and expression of P-glycoprotein in renal tubular epithelial cells determine susceptibility to chronic tubulointerstitial damage of transplanted kidneys.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19762492      PMCID: PMC2799173          DOI: 10.1681/ASN.2009020192

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  58 in total

1.  Protocol core needle biopsy and histologic Chronic Allograft Damage Index (CADI) as surrogate end point for long-term graft survival in multicenter studies.

Authors:  Serdar Yilmaz; Steven Tomlanovich; Timothy Mathew; Eero Taskinen; Timo Paavonen; Merci Navarro; Eleanor Ramos; Leon Hooftman; Pekka Häyry
Journal:  J Am Soc Nephrol       Date:  2003-03       Impact factor: 10.121

2.  Increased chimerism of bronchial and alveolar epithelium in human lung allografts undergoing chronic injury.

Authors:  Wolfram Kleeberger; Anne Versmold; Thomas Rothämel; Sabine Glöckner; Martin Bredt; Axel Haverich; Ulrich Lehmann; Hans Kreipe
Journal:  Am J Pathol       Date:  2003-05       Impact factor: 4.307

Review 3.  Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation.

Authors:  Christine E Staatz; Susan E Tett
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

4.  The natural history of chronic allograft nephropathy.

Authors:  Brian J Nankivell; Richard J Borrows; Caroline L-S Fung; Philip J O'Connell; Richard D M Allen; Jeremy R Chapman
Journal:  N Engl J Med       Date:  2003-12-11       Impact factor: 91.245

5.  Human pulmonary chimerism after hematopoietic stem cell transplantation.

Authors:  Benjamin T Suratt; Carlyne D Cool; Amanda E Serls; Lin Chen; Marileila Varella-Garcia; Elizabeth J Shpall; Kevin K Brown; G Scott Worthen
Journal:  Am J Respir Crit Care Med       Date:  2003-04-30       Impact factor: 21.405

6.  Natural history, risk factors, and impact of subclinical rejection in kidney transplantation.

Authors:  Brian J Nankivell; Richard J Borrows; Caroline L-S Fung; Philip J O'Connell; Richard D M Allen; Jeremy R Chapman
Journal:  Transplantation       Date:  2004-07-27       Impact factor: 4.939

Review 7.  Cyclosporine nephrotoxicity.

Authors:  Emmanuel A Burdmann; Takeshi F Andoh; Luis Yu; William M Bennett
Journal:  Semin Nephrol       Date:  2003-09       Impact factor: 5.299

8.  Glomerular enlargement assessed by paired donor and early protocol renal allograft biopsies.

Authors:  Gabriela Alperovich; Rafael Maldonado; Francesc Moreso; Xavier Fulladosa; Josep M Grinyó; Daniel Serón
Journal:  Am J Transplant       Date:  2004-04       Impact factor: 8.086

9.  Association between ABCB1 (multidrug resistance transporter) genotype and post-liver transplantation renal dysfunction in patients receiving calcineurin inhibitors.

Authors:  Mary F Hebert; Amy L Dowling; Cynthia Gierwatowski; Yvonne S Lin; Karen L Edwards; Connie L Davis; Christopher L Marsh; Erin G Schuetz; Kenneth E Thummel
Journal:  Pharmacogenetics       Date:  2003-11

10.  Tubular chimerism occurs regularly in renal allografts and is not correlated to outcome.

Authors:  Michael Mengel; Danny Jonigk; Magali Marwedel; Wolfram Kleeberger; Martin Bredt; Oliver Bock; Ulrich Lehmann; Wilfried Gwinner; Hermann Haller; Hans Kreipe
Journal:  J Am Soc Nephrol       Date:  2004-04       Impact factor: 10.121

View more
  37 in total

Review 1.  Assessment of kidney organ quality and prediction of outcome at time of transplantation.

Authors:  Thomas F Mueller; Kim Solez; Valeria Mas
Journal:  Semin Immunopathol       Date:  2011-01-28       Impact factor: 9.623

Review 2.  Molecular diagnostics in transplantation.

Authors:  Maarten Naesens; Minnie M Sarwal
Journal:  Nat Rev Nephrol       Date:  2010-08-24       Impact factor: 28.314

Review 3.  Senile nephrosclerosis--does it explain the decline in glomerular filtration rate with aging?

Authors:  Andrew D Rule; Lynn D Cornell; Emilio D Poggio
Journal:  Nephron Physiol       Date:  2011-08-10

4.  Donor P-gp polymorphisms strongly influence renal function and graft loss in a cohort of renal transplant recipients on cyclosporine therapy in a long-term follow-up.

Authors:  J-B Woillard; J-P Rerolle; N Picard; A Rousseau; A Guillaudeau; E Munteanu; M Essig; M Drouet; Y Le Meur; P Marquet
Journal:  Clin Pharmacol Ther       Date:  2010-05-26       Impact factor: 6.875

Review 5.  PharmGKB summary: cyclosporine and tacrolimus pathways.

Authors:  Julia M Barbarino; Christine E Staatz; Raman Venkataramanan; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2013-10       Impact factor: 2.089

Review 6.  Clinical implementation of pharmacogenetics in kidney transplantation: calcineurin inhibitors in the starting blocks.

Authors:  Laure Elens; Rachida Bouamar; Nauras Shuker; Dennis A Hesselink; Teun van Gelder; Ron H N van Schaik
Journal:  Br J Clin Pharmacol       Date:  2014-04       Impact factor: 4.335

7.  Progressive histological damage in renal allografts is associated with expression of innate and adaptive immunity genes.

Authors:  Maarten Naesens; Purvesh Khatri; Li Li; Tara K Sigdel; Matthew J Vitalone; Rong Chen; Atul J Butte; Oscar Salvatierra; Minnie M Sarwal
Journal:  Kidney Int       Date:  2011-08-31       Impact factor: 10.612

Review 8.  The influence of pharmacogenetics and cofactors on clinical outcomes in kidney transplantation.

Authors:  Nicolas Picard; Pierre Marquet
Journal:  Expert Opin Drug Metab Toxicol       Date:  2011-03-25       Impact factor: 4.481

Review 9.  Kidney Fibrosis: Origins and Interventions.

Authors:  Thomas Vanhove; Roel Goldschmeding; Dirk Kuypers
Journal:  Transplantation       Date:  2017-04       Impact factor: 4.939

10.  Donor ABCB1 variant associates with increased risk for kidney allograft failure.

Authors:  Jason Moore; Amy Jayne McKnight; Bernd Döhler; Matthew J Simmonds; Aisling E Courtney; Oliver J Brand; David Briggs; Simon Ball; Paul Cockwell; Christopher C Patterson; Alexander P Maxwell; Stephen C L Gough; Gerhard Opelz; Richard Borrows
Journal:  J Am Soc Nephrol       Date:  2012-10-11       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.